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Background: The TRACER trial compared vorapaxar, a novel oral PAR-1 antagonist, with placebo, as add-on therapy to standard of care, among 
12944 NSTE ACS patients who were predominantly treated with aspirin and clopidogrel. While vorapaxar was associated with a significant increase in 
major bleeding in the overall population, a lower bleeding hazard was observed in those without concomitant clopidogrel.
Methods: A substudy evaluated biologic parameters including platelet reactivity in the placebo and vorapaxar arms (n=249). Platelet aggregation 
(PA) in response to 20μM ADP, 15μM TRAP, and CAT (2.5μg/ml collagen related peptide + 5μM ADP + 15μM TRAP)), and P2Y12 signaling using the 
VASP assay were measured. Results were evaluated at baseline and at 1 mo. Onset of PAR-1 inhibition was evaluated by TRAP PA at 30 min, 1, 2, and 
4 hr post loading dose.
Results: At 1 mo TRAP PA was strongly inhibited by vorapaxar with all subjects having < 20% PA within 2-4 hr. ADP maximal and final (5 min post 
agonist) PA trended lower in the vorapaxar group vs placebo whereas CAT maximal and final PA were significantly lower in the vorapaxar arm. VASP 
Platelet Reactivity Index (PRI) was significantly lower in both treatment arms.
Conclusions: Vorapaxar had a consistently marked PA inhibition to the PAR-1 agonist TRAP. PAR-1 antagonism may downregulate P2Y12 dependent 
pathways affecting aggregate stability. Findings imply that concomitant PAR-1 and P2Y12 blockade in the background of aspirin may contribute to 




TRAP (15μM) n=33 n=33
Baseline 64 ± 15 60 ± 16
1 Month 63 ± 18 4 ± 4
p 0.650 < 0.001
ADP (20μM) n=35 n=33
Baseline 56 ± 17 55 ± 15
1 Month 52 ±22 48 ± 16
p 0.370 0.090
CAT n=34 n=31
Baseline 75 ± 10 74 ± 14
1 Month 72 ± 15 44 ± 18
p 0.159 0.001
Final Aggregation (FA)
ADP (20μM) n=35 n=31
Baseline 45 ± 22 43 ± 19
1 Month 41 ±27 34 ± 20
p 0.433 0.085
CAT n=34 n=31
Baseline 69 ± 14 67 ± 17
1 Month 63 ± 19 30 ± 22
p 0.067 < 0.001
VASP PRI (Baseline >75)
n=37 n=30
Baseline 83 ± 5 83 ± 4
1 Month 64 ± 24 57 ± 22
p < 0.001 < 0.001
